Thermo Fisher picks up mass spec software developer HighChem

Thermo Fisher Scientific headquarters
Earlier this year, Thermo Fisher announced plans to invest $150 million in its services aimed at the pharmaceutical industry. (Image: Thermo Fisher)

Thermo Fisher Scientific has absorbed HighChem, the Bratislava, Slovakia-based developer and trademark holder of the Mass Frontier mass spectrometry software used to identify the structures of small molecules.

HighChem’s work will be fully integrated into the chromatography and mass spec business within the company’s analytical instruments segment, though Thermo Fisher itself has been offering Mass Frontier for years. The financial terms of the deal were not disclosed.

HighChem and its small team of employees also develop library and cloud-based systems and maintain large data collections of fragmentation knowledge, experimental spectra and organism-specific biochemical data for use in biopharmaceutical, metabolomic, forensic and environmental applications.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Earlier this year, Thermo Fisher announced plans to invest $150 million in its services aimed at the pharmaceutical industry, including adding capacity for product development and manufacturing.

RELATED: Thermo Fisher to buy viral vector maker Brammer Bio for $1.7B

It plans to expand three of its CDMO locations in North Carolina and Italy over the next two years. Thermo Fisher had jumped headlong into the contract manufacturing business with its $7.2 billion deal for Patheon in 2017.

RELATED: Thermo Fisher launches 'smart' PCR systems with facial unlock, voice commands

Its $1.7 billion acquisition of viral vector developer and manufacturer Brammer Bio also gave it a foothold in the cell and gene therapy market. Thermo Fisher estimates the addition will deliver $250 million in annual revenue by the end of the year, and expects its growth to outpace the 25% rate projected for that sector.

Suggested Articles

GenapSys has unveiled its compact, high-throughput DNA sequencer, alongside a $90 million venture capital raise to help jump-start its launch.

LivaNova plans to restructure its heart valve operations, and will drop its investigational Caisson transcatheter mitral valve replacement altogether.

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.